Safety and efficacy of ibutilide in heart transplant recipients.
In this report we describe our experience with ibutilide, a relatively new Class III anti-arrhythmic agent, in 8 heart transplant patients with supraventricular tachycardia in various settings (3 patients with rejection, 2 after endomyocardial biopsy). Ibutilide treatment was successful in all patients, with the arrhythmia recurring early in 1 patient. There were no complications.
Division of Cardiovascular Disease, Section of Heart Failure, Transplantation and Pulmonary Vascular Disease, University of Alabama at Birmingham, Birmingham, AL 35294, USA. jtallaj@uab.edu
José A
JA
Tallaj
Veronica
V
Franco
Barry K
BK
Rayburn
Salpy V
SV
Pamboukian
Raymond L
RL
Benza
James K
JK
Kirklin
David C
DC
McGiffin
Melissa
M
Smallfield
Robert C
RC
Bourge
D000293:Adolescent; D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000503:physiopathology; D001282:Atrial Flutter / Q000188:drug therapy / Q000503:physiopathology; D054537:Atrioventricular Block / Q000188:drug therapy / Q000503:physiopathology; D001706:Biopsy; D004562:Electrocardiography / Q000187:drug effects; D004699:Endocardium / Q000473:pathology; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D016027:Heart Transplantation / Q000502:physiology*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000473:pathology; D011183:Postoperative Complications / Q000188:drug therapy* / Q000503:physiopathology; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D013617:Tachycardia, Supraventricular / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents; D013449:Sulfonamides; C067192:ibutilide